Review Article

Music and Dopamine – Potential in Movement Disorders

Ichiro Kawahata1*, Ruriko Kase2 and Kazuko Hasegawa3

1Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
2Japan Promotion Association of Piano Culture, Tokyo, Japan
3Department of Neurology, Sagamihara National Hospital, Sagamihara, Japan

ARTICLE INFO

Article history:
Received: 20 March, 2020
Accepted: 2 April, 2020
Published: 7 April, 2020

Keywords:
Parkinson’s disease
movement disorders
dopamine
tyrosine hydroxylase
ubiquitin-proteasome system
brain function
music
music therapy

ABSTRACT

Most people have been deriving pleasure from music since long ago. Music is deeply associated with human communication and language. Music had also been popular as therapy in early history. How can we feel happiness or sadness when we listen to music? Scientifically, the dorsal and ventral striatum release dopamine when listening to pleasurable music. The activity in these structures is known to associate with the reward system of the human brain. Moreover, the nigrostriatal dopaminergic system regulates our motor function, and this is the very part that is damaged in the movement disorders. In this article, we review the potent role of music from the viewpoint of the dopaminergic system. We also describe the molecular mechanism of the dopaminergic pathogenesis and suggest the potent ability of music for the therapy of Parkinson’s disease and related movement disorders.

© 2020 Ichiro Kawahata. Hosting by Science Repository. All rights reserved

History of Music and Humanity

Most people have been deriving pleasure from music since long ago. Music is deeply associated with human communication and language [1]. Music had also been popular as therapy in early history [2]. In general, one may conclude that music was frequently employed as a part of magical rituals to control the unpredictable and unexplainable forces of nature, to calm or satisfy metaphysical forces, such as gods or demons, and to combat disease and death. In early history, as still in evidence in preliterate societies, these three realms of control of nature, control or entreaties of supernatural forces, and control of life and health, must have been highly interwoven. In this context, Nettl refers to the importance of the physical response, in addition to the emotional response, to music by the human organism [3]. Not only does the sound production create a physical behavior and general bodily attitude specific to the desired sound, but the structures within the music could also create specific physical responses.

Music and Clinical Effects

Some Ancient Greeks considered music as therapeutic in more direct ways – reflecting and projecting the harmony of the cosmos onto the mind and thus creating or reestablishing inner harmony. This process was considered not only valuable as therapy, but also for educational purposes to strengthen character and virtue. The Aristotelians added a new emphasis, explicitly introducing the therapeutic function of affective “catharsis” induced by music to relieve the mind from negative emotions. We also know from the writings of the physician Asclepiades about specific “clinical” prescriptions of music therapy for the treatment of mental disorders [2].

Music therapy has the unique ability to promote neuroplasticity through the increase of dopamine production, the synchrony of neural firing, and the production of a clear signal. Much of what is taught and inherently known in music therapy has roots in neuroplasticity. Music therapists are taught to pair non-music tasks/behavior with music. This in itself is a
basic principle of neuroplasticity, but now there is more research supporting music as a rich neuroplasticity tool. What makes music therapy work, though, is the ability of music therapists to know how to use/manipulate music to shape the neural responses that underlie client/patient behavior [4].

Music and Dopaminergic Functions

How can we feel happiness or sadness when we listen to music? Scientifically, the dorsal and ventral striatum release dopamine when listening to pleasurable music. The activity in these structures is known to associate with the reward system of the human brain. Moreover, the striatum interacts with cortical mechanisms involved in the perception and valuation of musical stimuli. In detail, listening to music stimulates the nigrostriatal dopaminergic system, as well as the nucleus accumbens and ventral tegmental area in the mesolimbic pathway [5-10]. Additionally, listening to pleasurable music facilitates neuroplasticity, as well as movement, breathing, and heart rate, indicating the immense potential of music in the therapy for dementia and movement disorders, including Alzheimer's disease and Parkinson's disease [11-14].

Regulation of Dopamine Biosynthesis

Dopamine is biosynthesized from L-tyrosine by tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase (AADC) [15, 16]. TH is responsible for catalyzing the conversion of the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), and subsequently, L-DOPA is converted to dopamine by AADC. Tetrahydrobiopterin (BH4), which is biosynthesized by GTP cyclohydrolase I (GTPCHI), is required for the enzymatic activity of TH. Unlike other enzymes, the TH protein has its enzymatic activity strictly controlled at the rate-limiting step of dopamine biosynthesis [17, 18]. TH expression level and activity are directly involved in regulating intracellular dopamine levels. The activity of TH can be modulated by two mechanisms: medium- to long-term regulation of gene expression, for example by the effect on enzyme stability, transcription, RNA stability, alternative RNA splicing, and translation; and short-term regulation of enzyme activity, for example by feedback inhibition, allosteric regulation, and phosphorylation. Regulation of TH expression is dependent on a cAMP-dependent responsive element (CRE), AP-1, ATF-2, and Nurr1 [18-22].

Molecular Mechanism of Dopaminergic Pathogenesis

The reduction of the nigrostriatal TH protein level is a pathological feature of Parkinson's disease. Contrary to the decrease in the protein level, TH activity from parkinsonian tissue was reportedly increased by 48% compared to controls, or activity per enzyme protein of TH in the parkinsonian nigrostriatal region was elevated by 3-4-fold [23, 24]. The increased activity of residual TH in the parkinsonian brain suggests the facilitation of TH phosphorylation as a result of a compensatory increase in TH activity to compensate for the loss of dopamine caused by the disease [25]. In fact, we previously reported that dopamine or biotinper deficiency potentiates TH phosphorylation [26]. It is noteworthy that the potentiated TH phosphorylation is accompanied by degradation of TH protein by the ubiquitin-proteasome system [26, 27]. This mechanism suggests the possibility that the dysfunction of dopamine biosynthesis in dopamine-related disorders such as Parkinson’s disease and dopa-responsive dystonia leads to the induction of TH phosphorylation, which is accompanied by a reduced total TH protein level induced by degradation via the ubiquitin-proteasome system.

Consistently, phosphorylation of the N-terminal portion of TH reportedly triggers proteosomal digestion of the enzyme [28]. Phosphorylated TH also easily aggregates to form intracellular inclusions by proteosomal inhibition [27]. The activity of proteasome is reduced in Parkinson’s disease [29, 30]. These phenomena suggest a putative mechanism in which elevation of TH phosphorylation to prevent a lack of dopamine in Parkinson’s disease leads to the formation of intracellular aggregates of TH protein. Indeed, Lewy bodies are phosphorylated TH-immunopositive in the brains of patients with Parkinson’s disease [31]. These data suggest that phosphorylated TH is vulnerable and that the dopamine-deficient state in Parkinson’s disease and related disorders may accelerate the decrease in TH protein level through the degradation or accumulation-induced aggregation of phosphorylated TH.

Advances in Therapies for Parkinson’s Disease

Fundamental therapies for Parkinson’s disease are not yet well established. Almost half a century after it was first introduced, L-DOPA (C9H11NO4) is still the most effective medication available for the palliative treatment of the motor symptoms in Parkinson’s disease [32, 33]. Recent progress of treatment technique for Parkinson's disease is remarkable; deep brain stimulation is efficacious in the treatment of Parkinsonian tremor, striatal injection of AADC-coding vectors stably restore the response to L-DOPA and contribute to a decrease of the effective L-DOPA dose, and stem cell transplantation therapies may effectively restore and replace cells in the damaged tissues [34-36]. Interestingly, music therapy is popular in medical care for Parkinson's disease, as well as pharmacotherapeutic development to potentiate dopamine biosynthesis, and the combination [37-41]. In fact, listening to music reportedly facilitates dopaminergic neurotransmission in a calcium/calmodulin-dependent manner [42, 43]. This phenomenon suggests the potential mechanism to facilitate CRE-mediated TH gene expression by the activation of calcium/calmodulin-dependent kinase II [44]. These reports mentioned above raise the expectations for fundamental therapeutics and the benefits of music in neurodegenerative disorders.

Future of Music and Dopaminergic Disorders

Parkinson’s disease and related disorders are currently difficult to fundamentally cure. However, although fundamental therapies have not been established, the development of novel therapeutics is remarkable. The combination of medical therapeutics and listening to music, singing songs as well as playing instruments can improve not only the motor function, but also the emotional and cognitive system. We had spread the Kodály method-based piano culture in Japan, which is based on the musical education established by Zoltán Kodály. It is already adopted as Community Music Therapy for the social and psychological aspects of the illness [45]. We further pray for harmony for the development of pharmacotherapeutics, diagnostic tools, and musical therapies for Parkinson’s disease and related dopaminergic disorders.
Acknowledgements

We all pay our respects to Mrs. Runiko Kase, a great pianist, and the best educator commended by Who’s Who, the deceased representative of Japan Promotion Association of Piano Culture (JPAPC). We also thank Mrs. Tusa Erzsebet, a Professor in Liszt Ferenc Academy of Music in Hungary, for her tremendously warm piano education. The following grants support a part of the data shown in this review; Kobayashi International Scholarship Foundation, Intelligent Cosmos Award Research Grant, Smoking Science Research Foundation, MEXT/JSPS KAKENHI 16K08904, Sasakawa Science Research Grant, Nakatomi Health Science Foundation, MEXT/JSPS KAKENHI 23790594, and MEXT/JSPS KAKENHI 30579743 to I.K.

References

1. Fitch WT (2006) The biology and evolution of music: a comparative perspective. Cognition 100: 173-215. [Crossref]
2. Thaut MH (2015) Music as therapy in early history. Prog Brain Res 217: 143-158. [Crossref]
3. Nettl B (1955) Change in Folk and Primitive Music: A Survey of Methods and Studies. J Am Music Society 8: 101-109.
4. Stegemoller EL (2014) Exploring a neuroplasticity model of music therapy. J Music Ther 51: 211-227. [Crossref]
5. Menon V, Levitin DJ (2005) The rewards of music listening: response and physiological connectivity of the mesolimbic system. Neuroimage 28: 175-184. [Crossref]
6. Salimpoor VN, Benovsky M, Larcher K, Dagher A, Zatorre RJ (2011) Anatomically distinct dopamine release during anticipation and experience of peak emotion to music. Nat Neurosci 14: 257-262. [Crossref]
7. Koelsch S, Fritz T, DY VC, Muller K, Friederici AD (2006) Investigating emotion with music: an fMRI study. Hum Brain Mapp 27: 239-250. [Crossref]
8. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward? hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 30: 309-369. [Crossref]
9. Ferreri L, Mas Herrera E, Zatorre RJ, Ripoles P, Gomez Andres A et al. (2019) Dopamine modulates the reward experiences elicited by music. Proc Natl Acad Sci U S A 116: 3793-3798. [Crossref]
10. Goupil L, Aouctourier JJ (2019) Musical pleasure and musical emotions. Proc Natl Acad Sci U S A 116: 3364-3366. [Crossref]
11. Duarte A, Henson RN, Knight RT, Emery T, Graham KS (2010) Orbito-frontal cortex is necessary for temporal context memory. J Cogn Neurosci 22: 1819-1831. [Crossref]
12. Paulmann S, Seifert S, Kotz SA (2010) Orbito-frontal lesions cause impairment during late but not early emotional prosodic processing. Soc Neurosci 5: 59-75. [Crossref]
13. Muller V, Lindenberger U (2011) Cardiac and respiratory patterns synchronize between persons during choir singing. PLoS One 6: e24893. [Crossref]
14. Miendlarzewska EA, Trost WJ (2014) How musical training affects cognitive development: rhythm, reward and other modulating variables. Front Neurosci 7: 279. [Crossref]
15. Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine Hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239: 2910-2917. [Crossref]
16. Blaschko H (1942) The activity of l (-)-dopa decarboxylase. J Physiol 101: 337-349. [Crossref]
17. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy Fehsobuki EI, Dickson PW (2004) Tyrosine hydroxylase phosphorylation: regulation and consequences. J Neurochem 91: 1025-1043. [Crossref]
18. Kumer SC, Vrana KE (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67: 443-462. [Crossref]
19. Chae HD, Suh BC, Joh TH, Kim KT (1996) API-mediated transcriptional enhancement of the rat tyrosine hydroxylase gene by muscarinic stimulation. J Neurochem 66: 1264-1272. [Crossref]
20. Guo Z, Du X, Iacovitti L (1998) Regulation of tyrosine hydroxylase gene expression during transdifferentiation of striatal neurons: changes in transcription factors binding the AP-1 site. J Neurosci 18: 8163-8174. [Crossref]
21. Suzuki T, Yamakuni T, Hagiwara M, Ichinose H (2002) Identification of ATF-2 as a transcriptional regulator for the tyrosine hydroxylase gene. J Biol Chem 277: 40768-40774. [Crossref]
22. Kadkhodaei B, Ito T, Joodmardi E, Mattsson B, Rouillard C et al. (2009) Nur1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci 29: 15923-15932. [Crossref]
23. Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50: 202-208. [Crossref]
24. Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T et al. (1998) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72: 77-82. [Crossref]
25. Nagatsu T (1990) Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity. Neurochem Res 15: 425-429. [Crossref]
26. Kawahata I, Ohtaku S, Tomioka Y, Ichinose H, Yamakuni T (2015) Dopamine or biotin deficiency potentiates phosphorylation at (40)Ser and ubiquitination of tyrosine hydroxylase to be degraded by the ubiquitin proteasome system. Biochem Biophys Res Commun 465: 53-58. [Crossref]
27. Kawahata I, Tokuoka H, Parvez H, Ichinose H (2009) Accumulation of phosphorylated tyrosine hydroxylase into insoluble protein aggregates by inhibition of an ubiquitin-proteasome system in PC12D cells. J Neural Transm (Vienna) 116: 1571-1578. [Crossref]
28. Nakashima A, Mori K, Kaneko HS, Hayashi N, Nagatsu T et al. (2011) Phosphorylation of the N-terminal portion of tyrosine hydroxylase triggers proteasomal digestion of the enzyme. Biochem Biophys Res Commun 407: 343-347. [Crossref]
29. McNaught KS, Olanow CW (2003) Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 53: S73-S86. [Crossref]
30. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2: 589-594. [Crossref]
31. Kawahata I, Yagishita S, Hasegawa K, Nagatsu I, Nagatsu T et al. (2009) Immunohistochemical analyses of the postmortem human
Music for Movement Disorders

brains from patients with Parkinson's disease with anti-tyrosine hydroxylase antibodies. *Bioorg Amines* 23: 1-7.

32. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of Parkinsonism—chronic treatment with L-dopa. *N Engl J Med* 280: 337-345. [Crossref]

33. Fernandez HH (2015) 2015 Update on Parkinson disease. *Cleve Clin J Med* 82: 563-568. [Crossref]

34. Miocinovic S, Somayajula S, Chitnis S, Vitek JL (2013) History, applications, and mechanisms of deep brain stimulation. *JAMA Neurol* 70: 163-171. [Crossref]

35. Coune PG, Schneider BL, Aebischer P (2012) Parkinson's disease: gene therapies. *Cold Spring Harb Perspect Med* 2: a009431. [Crossref]

36. Fu MH, Li CL, Lin HL, Chen PC, Calkins MJ et al. (2015) Stem cell transplantation therapy in Parkinson's disease. *Springerplus* 4: 597. [Crossref]

37. Pacchetti C, Mancini F, Aglieri R, Fundaro C, Martignoni E et al. (2000) Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. *Psychosom Med* 62: 386-393. [Crossref]

38. Pacchetti C, Aglieri R, Mancini F, Martignoni E, Nappi G (1998) Active music therapy and Parkinson's disease: methods. *Funct Neurol* 13: 57-67. [Crossref]

39. Kawahata I, Lai Y, Morita J, Kato S, Ohtaku S et al. (2017) V-1/CP complex formation is required for genetic co-regulation of adult nigrostriatal dopaminergic function via the RHO/MAL/SRF pathway in vitro and in vivo. *J Neurol Sci* 381: 359-360.

40. Kawahata I (2019) Drug discovery study of fundamental therapy for dopamine related diseases targeting new V-1 / CP complex. *Impact 2019*: 49-51.

41. Garcia Casares N, Martin Colom JE, Garcia Armes JA (2018) Music Therapy in Parkinson's Disease. *J Am Med Dir Assoc* 19: 1054-1062. [Crossref]

42. Sutoo D, Akiyama K (2004) Music improves dopaminergic neurotransmission: demonstration based on the effect of music on blood pressure regulation. *Brain Res* 1016: 255-262. [Crossref]

43. Akiyama K, Sutoo D (2011) Effect of different frequencies of music on blood pressure regulation in spontaneously hypertensive rats. *Neurosci Lett* 487: 58-60. [Crossref]

44. Matthews RP, Guthrie CR, Wailes LM, Zhao X, Means AR et al. (1994) Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. *Mol Cell Biol* 14: 6107-6116. [Crossref]

45. Tiszai L (2015) Kodaly Approach in the Crossroad of Education and Therapy. *Voices* 15.